Amundi’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Amundi’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,496	Closed	-$969K	–	2072
2025 Q4	$969K	Buy	+23,496	New	+$943K	﹤0.01%	1276
2025 Q3	–	Sell	-15,972	Closed	-$438K	–	1639
2025 Q2	$438K	Hold	15,972	–	–	﹤0.01%	1411
2025 Q1	$348K	Buy	+15,972	New	+$329K	﹤0.01%	1573
2023 Q4	–	Sell	-5,770	Closed	-$94.1K	–	2035
2023 Q3	$94.1K	Buy	+5,770	New	+$97.2K	﹤0.01%	1769

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Amundi's KNSA Position: Q1 2026 in Review

Amundi sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 23,496 shares — an estimated $969K sold.

Amundi first reported a position in KNSA in Q3 2023 and held it in 4 quarters. The position peaked at $969K in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Amundi reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Amundi sold 23,496 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $969K.
Amundi first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and held it in 4 quarters.
Amundi's Kiniksa Pharmaceuticals position peaked at $969K in Q4 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.